title: Characterization of clinical strains of Aspergillus terreus complex: molecular identification and antifungal susceptibility to azoles and amphotericin B.
abstract: We used molecular techniques to analyse 87 (n = 70 patients) Aspergillus terreus complex isolates, all of which were identified as A. terreus sensu stricto. The antifungal susceptibilities determined with CLSI M38-A2 (and Etest for amphotericin B) and expressed as mg/L for range of MIC/MIC(90) /geometric mean were as follows: itraconazole, 0.25-2/2/1.097; voriconazole, 0.125-2/2/1.176; posaconazole, 0.25-1/1/0.836; amphotericin B CLSI, 4-32/16/9.689; and Etest, 0.75-64/6/3.106. The MICs for amphotericin B were significantly higher than those found for the triazoles.
authors: Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain.
authors: P
authors: P
authors: Escribano
authors: T
authors: T
authors: Peláez
authors: S
authors: S
authors: Recio
authors: E
authors: E
authors: Bouza
authors: J
authors: J
authors: Guinea
mesh_terms: D000666:Amphotericin B / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D001228:Aspergillosis / Q000382:microbiology*; D001230:Aspergillus / Q000145:classification* / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D001393:Azoles / Q000494:pharmacology*; D016000:Cluster Analysis; D004271:DNA, Fungal / Q000737:chemistry / Q000235:genetics; D004275:DNA, Ribosomal / Q000737:chemistry / Q000235:genetics; D021903:DNA, Ribosomal Spacer / Q000737:chemistry / Q000235:genetics; D006801:Humans; D008826:Microbial Sensitivity Tests; D009172:Mycology / Q000379:methods; D010802:Phylogeny; D012340:RNA, Ribosomal, 5.8S / Q000235:genetics; D017422:Sequence Analysis, DNA
chemical_list: D000935:Antifungal Agents; D001393:Azoles; D004271:DNA, Fungal; D004275:DNA, Ribosomal; D021903:DNA, Ribosomal Spacer; D012340:RNA, Ribosomal, 5.8S; D000666:Amphotericin B